Optimising Inbound Logistics at a Pharmaceutical Company
Mid-sized pharmaceutical company with a growing supply chain
Undefined processes and unclear responsibilities led to delays and rising costs in inbound logistics.
The challenge
The situation
A lack of defined processes and unclear responsibilities in inbound logistics led to delays and rising costs. The absence of a structured approach hampered the timely delivery of raw materials and called for a comprehensive strategy for clear responsibilities.
Our approach
What we delivered
Complete mapping of the inbound-logistics value chain
Building a RACI matrix to clarify responsibilities
Definition of a project plan for implementation
The outcome
Results & impact
Five core areas analysed
End-to-end analysis of five areas of inbound logistics.
RACI matrix established
Clear responsibilities defined along the entire value chain.
In summary
The company has clearly defined responsibilities and a structured inbound logistics function as the basis for timely material delivery.
Related expertise
Logistikoptimierung →
Most direct match: the case study is at its core a project to optimise the inbound-logistics processes of a pharmaceutical company.
Lieferkettenmanagement →
The case study addresses exactly this topic: a more stable, more efficient supply chain through clear processes and responsibilities.
Supply Chain Governance →
The RACI matrix and the central communication framework from the approach correspond to classic supply-chain-governance work.
Manufacturing & Supply Chain Management →
The case study concerns safeguarding delivery capability along the chain through to timely delivery of raw materials, as described in this expertise.
Similar projects
More on Pharma →
Sources
- Entourage project experience (anonymised)
Your project
A comparable project?
Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.
Prefer direct? +41 61 271 23 80
info@theentourage.ch
- Reply usually within one working day
- 4 offices: DE · CH · IT · US
- 100% life sciences